Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-08-13
1998-07-21
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514 21, A61K 3800, A61K 3824, A61K 3830
Patent
active
057835560
ABSTRACT:
Formulations containing NPH insulin are useful for treating hyperglycemic disorders, such as diabetes, in a mammal in need of treatment. One such formulation, which is preferably administered parenterally, more preferably by injection, comprises IGF-I and NPH insulin, in amounts of from or about 1 to 10 mg IGF-I and from or about 0.2 to 2 mg NPH insulin in a pharmaceutically acceptable carrier. Another such formulation comprises IGF-I and NPH insulin in an acetic acid salt buffer. Still another formulation comprises IGF-I and NPH insulin in a weight ratio of NPH insulin to IGF-I of from or about 10:1 to 1:50 (w/w), from or about 0.05 to 0.3M of an osmolyte, from or about 0.1 to 10 mg/mL of a stabilizer, and from or about 5 to 100 mM of a buffer at from or about pH 5 to 7. A still further composition comprises NPH insulin in an acetic acid salt buffer.
REFERENCES:
patent: 4988675 (1991-01-01), Froesch et al.
The Merck Index, Budavari, ed., 11th edition, Rahway, NJ:Merck & Co., Inc. p. 49 (1989).
Amiel et al., "Effect of Diabetes and its COntrol on Insulin-like Growth Factors in Young Subject with Type I Diabetes" Diabetes 33(12):1175-1179 (Dec. 1984).
Arias et al., "Suppression of the Dawn Phenomenon by Somatostatin" Diabetologia 27(2):252A (abstract only 1984).
Baxter, R.C., "The Somatomedins: Insulin-Like Growth Factors" Advances in Clin Chem. 25:49-115 (1986).
Binoux, M., "Donnees recentes sur les somatomedines" Annales d'Endocrinologie 41:157-191 (1980).
Blethen et al., "Effect of Pubertal Stage and Recent Blood Glucose Control on Plasma Somatomedin C in Children with Insulin-dependent Diabetes Mellitus" Diabetes 30:868-872 (1981).
Boulware et al., "Phosphate and Potassium Lowering Effects of Insulin-like Growth Factor-I in Humans: Comparison with Insulin" The Endocrine Society, San Antonio, (74th Annual Meeting) pp. 78:106 (abstract only) Jun. 1992).
Brismar et al., "Effect of Insulin on the Hepatic Production of Insulin-like Growth Factor-Binding Protein-1 (IGFBP-1), IGFBP-3, and IGF-I in Insulin-Dependent Diabetes" J. Clin. Endocrinol. Metab. 79(3):872-878 (1994).
Campbell, "The Evolution of Insulin Therapy" Pharmacy Times, Romaine Pierson vol. 59:40-44 (Oct. 1993).
Campbell et al., "Pathogenesis of the Dawn Phenomenon in Patients with Insulin-Dependent Diabetes Mellitus" New England J. of Medicine 312(23):1473-1479 (1985).
Campbell et al., "Prevention of the Dawn Phenomenon (Early Morning Hyperglycemia) in Insulin-Dependent Diabetes Mellitus by Bedtime Intranasal Administration of a Long-Acting Somatostatin Analog" Metabolism 37(1):34-37 (1988).
Cheetham et al., "The Effects of Recombinant Human Insulin-like Growth Factor I on Growth Hormone Secretion in Adolescents With Insulin Dependent Diabetes Mellitus" Clin. Endocrinol. 40:515-522 (1994).
Cheetham et al., "The Effects of Recombinant Insulin-like Growth Factor I Administration on Growth Hormone Levels and Insulin Requirements in Adolescents With Type I (Insulin-dependent) Diabetes Mellitus" Diabetologia 36:678-681 (1993).
Clemmons and Van Wyk, "Somatomedin: physiological control and effects on cell proliferation" Handbook Exp. Pharmacol. 57:161-208 (1981).
Davidson et al., "Suppression of Sleep-Induced Growth Hormone Secretion by Anticholinergic Agent Abolishes Dawn Phenomenom" Diabetes 37:166-171 (1988).
De Feo et al., "A Growth Hormone-induced Hepatic Insulin Resistance, Not an Increase in Plasma Insulin Clearance, is the Cause of the Dawn Phenomenom in Type I (insulin-dependent) Diabetes" Diabetologia (abstract only) 29:532A (1986).
Diabetes Control and Complications Trial Research, "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-term Complications in Insulin-dependent Diabetes Mellitus" New England J. of Medicine 329(14):977-986 (1993).
Dunger et al., "Insulin-like Growth Factors (IGFs) and IGF-I Treatment in the Adolescent With Insulin-dependent Diabetes Mellitus" Metabolism 44(10):119-123 (Suppl. 4 1995).
Edge et al., "Increased Overnight Growth Hormone Concentrations in Diabetic Compared With Normal Adolescents" J. Clin. Endocrinol Metab. 71(5):1356-1362 (1990).
Eizirik et al., "Insulin-Like Growth Factor I Does not Inhibit Insulin Secretion in Adult Human Pancreatic Islets in Tissue Culture" European J. of Endocrinology 133(2):248-250 (1995).
Elahi et al., "Hemodynamic and metabolilc responses to human insulin-like growth factor I (IGF-I) in men" Modrn Concepts of Insulin-Like Growth Factors, Spencer, EM, ed., New York:Elsevier Science Publ. Co. pp. 219-224 (1991).
Froesch et al., "Metabolic and Therapeutic Effects of Insulin-Like Growth Factor I" Horm. Res. 42:66-71 (1994).
Fuller et al., "Stimulation of Cardiac Protein Synthesis by Insulin-like Growth Factors" Biochemical Society Transactions 19:277S (1991).
Furnsinn et al., "Insulin-Like Growth Factor-I Inhibits Insulin and Amylin Secretion in Conscious Rats" Endocrinology 135(5):2144-2149 (1994).
Guler et al., "Effects of Insulin-like Growth Factor I in Man" Acta Paediatr. Scand. 367:52-54 (Suppl. 1990).
Guler et al., "Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults" New England J. of Medicine 317(3):137-140 (1987).
Gunn, et al., "Anabolic Steroids do not Alter the Effect of Insulin and IGF-2 on Protein Breakdown in L6 Muscle Cells" Biochem. Arch. 5:53-59 (1989).
Hall et al., "Serum Levels of Insulin-like Growth Factor (IGF) I, II and IGF Binding Protein in Diabetic Adolescents Treated With Continuos Subcutaneous Insulin Infusion" J. Inter. Med. 225:273-278 (1989).
Hermansen et al., "Diurnal Plasma Profiles of Metabolite and Hormone Concentration in Insulin-dependent Diabetic Patients During Conventional Insulin Treatment and Continuous Subcutaneous Insulin Infusion" Acta Endocrinol. (Copenh) 114:433-439 (1987).
Jabri et al., "Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients" Diabetes 43:369-374 (1994).
Jacob et al., "Metabolic Effects of IGF-I and Insulin in Spontaneouosly Diabetic BB/w Rats" Am. J. Physiol. 206:E262-E268 (1991).
Johansen et al., "Diurnal Serum Growth Hormone Levels in Poorly and Well-controlled Juvenile Diabetics" Diabetes 20:239-245 (Apr. 1971).
Kerr et al., "Effect of Insulin-like Growth Factor I on the Responses to and Recognition of Hypoglycemia" American Diabetes Association (ADA), San Antonio, Texas, Jun. 20-23, 1992 (abstract), 52nd Annual Meeting edition.
Kerr et al., "Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans" J. Clin. Invest. 91:141-147 (1993).
Kissel et al., "Applikatiosformen des Insulins (Forms of Administration of Insulin--English translation provided)" Deutsche Apotheker-Zeitung (Germany) 134(7):25-39 (1994).
Kuzuya et al., "Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes" Diabetes 42:696-705 (1993).
Lanes et al., "Impaired Somatomedin Generation Test in Children With Insulin-dependent Diabetes Mellitus" Diabetes 34:156-160 (1985).
Leahy et al., "Insulin-Like Growth Factor-I at Physiological Concentrations is a Potent Inhibitor of Insulin Secretion" Endocrinology 126(3):1593-1598 (1990).
Lewitt et al., "Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels" Endocrinology 129(4):2254-2265 (1991).
Lieberman et al., "Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans" J. Clin. Endocrinol. and Metab. 75(1):30-36 (1992).
Mathe, "Relations of Hormones and Growth Factors at the Crossroad of Pathogenesis and Pharmacotherapeutics. The Case of Diabetes Mellitus" Biomedicine and Pharmacotherapy 49/5:221-224 (1995).
Molnar et al., "Diurnal Growth Hormone and Glucose Abnormalities in Unstable Diabetics: Studies of Ambulatory-fed Subjects During Continuous Blood Glucose Analysis" J. Clin. Endocrin. Metab. 34(5):837-846 (1972).
Morrow et al., "Recombinant Human (rh) IGF-1 Reverses Hyperglycemia and Improves Insulin Sensuitivity in Severe
Clark Ross G.
Oeswein James Q.
Yeung Douglas A.
Genentech Inc.
Hasak Janet E.
Touzeau P. Lynn
Tsang Cecilia J.
LandOfFree
Formulated insulin-containing composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulated insulin-containing composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulated insulin-containing composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1647184